- Home
- CXW vs EWTX Comparison
CXW vs EWTX Comparison
Compare CXW & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXW
- EWTX
- Stock Information
- Founded
- CXW 1983
- EWTX 2017
- Country
- CXW United States
- EWTX United States
- Employees
- CXW N/A
- EWTX N/A
- Industry
- CXW Real Estate Investment Trusts
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- CXW Real Estate
- EWTX Health Care
- Exchange
- CXW Nasdaq
- EWTX Nasdaq
- Market Cap
- CXW 2.0B
- EWTX 2.3B
- IPO Year
- CXW 1997
- EWTX 2021
- Fundamental
- Price
- CXW $20.41
- EWTX $23.27
- Analyst Decision
- CXW Buy
- EWTX Buy
- Analyst Count
- CXW 3
- EWTX 8
- Target Price
- CXW $24.67
- EWTX $45.38
- AVG Volume (30 Days)
- CXW 1.2M
- EWTX 1.5M
- Earning Date
- CXW 05-07-2025
- EWTX 03-03-2025
- Dividend Yield
- CXW N/A
- EWTX N/A
- EPS Growth
- CXW 5.08
- EWTX N/A
- EPS
- CXW 0.62
- EWTX N/A
- Revenue
- CXW $1,961,646,000.00
- EWTX N/A
- Revenue This Year
- CXW $2.57
- EWTX N/A
- Revenue Next Year
- CXW $9.89
- EWTX N/A
- P/E Ratio
- CXW $32.92
- EWTX N/A
- Revenue Growth
- CXW 3.43
- EWTX N/A
- 52 Week Low
- CXW $10.74
- EWTX $14.90
- 52 Week High
- CXW $24.99
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- CXW 56.56
- EWTX 39.59
- Support Level
- CXW $20.05
- EWTX $21.58
- Resistance Level
- CXW $20.75
- EWTX $25.36
- Average True Range (ATR)
- CXW 0.62
- EWTX 2.13
- MACD
- CXW 0.11
- EWTX -0.24
- Stochastic Oscillator
- CXW 75.50
- EWTX 24.44
About CXW CoreCivic Inc.
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.